Press Releases

PTC is committed to serving the interests of all our stakeholders.
Pam & Kelsey
Living with PKU, United States

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Nov 03, 2015
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Nov. 3, 2015 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced  that management will present a company update at the following conferences: Credit Suisse 24 th Annual Healthcare Conference, on Wednesday, November 11 th at 8:30 a.m.
Read More
Oct 15, 2015
PTC Announces Results from Phase 3 ACT DMD Clinical Trial of Translarna™ (ataluren) in Patients with Duchenne Muscular Dystrophy
- PTC plans to complete rolling NDA submission to the FDA by end of 2015 -
- Totality of clinical data demonstrate Translarna's ability to slow disease progression for patients with nonsense mutation Duchenne muscular dystrophy -
- 15 meter benefit observed in 6MWD in overall study population (p=0.213, n=228) -
- 47 meter benefit observed in 6MWD in pre-specified subgroup of 300 - 400 meters at baseline (p=0.007, n=99) -
- Pre-specified meta-analysis of combined ACT DMD and Phase 2b studies demonstrated benefit in Translarna-treated patients across primary (p=0.015, n=291) and key secondary efficacy endpoints -
- Strong safety profile of Translarna confirmed, consistent with previous studies -
--Conference call scheduled today at 5:00 PM ET--
Read More